Stereotactic Body Radiotherapy for Extracranial Oligometastatic Breast Cancer A Multi-Institutional Retrospective Study

What this Trial Is About

Oligometastatic breast cancer occurs when breast cancer has spread to a limited number of other body sites. Patients with this condition may live longer than those with more widespread metastases. Researchers are investigating whether adding local treatments like stereotactic body radiotherapy SBRT, a non-invasive radiation therapy delivering high doses in a few sessions, can improve disease control and survival in these patients. This study is a multicenter retrospective analysis aiming to better understand SBRTs role in this setting. The study focuses on patients who have received SBRT to their oligometastatic sites, delivering a minimum radiation dose of 50 Gy EQD2 in up to 12 sessions, following the Oligocare definition. This local treatment is considered alongside standard systemic therapies like chemotherapy or hormonal therapy. The study collects data from treatments performed between January 2010 and December 2023 to evaluate outcomes. Participants data will be reviewed retrospectively to measure progression-free survival as the primary outcome. Secondary outcomes include local control of treated sites, overall survival, and acute or late radiation-related toxicities. The study covers treatments applied outside the brain and aims to provide insights into the safety and effectiveness of SBRT in managing oligometastatic breast cancer. The overall participation involves analysis of existing patient records from multiple centers up to the end of 2023.

stereOtactic Body RadIothErapy for exTracranial oligomeTastAtic Breast Cancer: Multi Institutional Retrospective Database